Drugs / GS3-007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05921890 | Jun → Oct 2023 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05611281 | Sep 2022 → Apr 2023 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS3-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05611281 ↗ |
| Route | Oral | “GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication” NCT05611281 ↗ |